Home>Topics>Stocks>Biomarin Pharmaceutical

Biomarin Pharmaceutical BMRN

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. With An Iffy Non-Oncology Pipeline, Roche Pays Up For InterMune

      Headlines

      Tue, 26 Aug 2014

      remained a frequent flier whenever an analyst or writer has wanted to write up a story on potential biotech/pharma M&A - Roche has been tied to Alexion (NASDAQ: ALXN ), BioMarin (NASDAQ: BMRN ), and Chugai on the more Complete Story »

    2. New Morningstar Analyst Report for Biomarin Pharmaceutical Inc

      Stock Reports

      Tue, 5 Aug 2014

      Accurate diagnosis of rare genetic diseases can be difficult, and BioMarin could have a hard time locating enough patients to recoup development and manufacturing scale-up costs.BioMarin's newest Phase III drug candidates could have high hurdles for approval; Pompe disease drug BMN 701 is going

    3. BioMarin Pharmaceutical's ( BMRN ) CEO Jean-Jacques Bienaimé on Q2 2014 Results - Earnings Call Transcript

      Headlines

      Wed, 30 Jul 2014

      BioMarin Pharmaceutical (NASDAQ: BMRN ) Q2 2014 Earnings Call July 30, 2014 4:30 pm ET Executives Traci McCarty - Jean-Jacques Bienaimé - Chief Executive Officer

    4. Biomarin ups guidance after Q2 results

      Headlines

      Wed, 30 Jul 2014

      Biomarin Pharmaceutical ( BMRN +0.1% ) Q2 results : Total Revenues: $191.8M (+40.2%); Operating Expenses: $210.7M (+34.3%); Operating

    5. BioMarin Pharmaceutical beats by $0.21, beats on revenue

      Headlines

      Wed, 30 Jul 2014

      BioMarin Pharmaceutical (NASDAQ: BMRN ): Q2 EPS of -$0.23 beats by $0.21 . Revenue of $191.79M (+40.2% Y/Y) beats by $32.09M . Shares +3.1% . Press Release Post your comment!

    6. Notable earnings after Wednesday’s close

      Headlines

      Tue, 29 Jul 2014

      ABX , AEL , AEM , AKAM , ALB , ALL , ALLE , AMC , ANIK , ARII , ASGN , ATEN , ATW , AUY , AVG , BALT , BGC , BMRN , CATM , CAVM , CBT , CENX , CHDN , CJES , CLUB , CMO , CNL , CNW , CODE , COHR , CTRP , CW , CWT , DDR , DRE , DRIV , EGN , EHTH

    7. A Young Power Couple's Kickstart Portfolio

      Headlines

      Fri, 6 Jun 2014

      184 0.07 N/A Matt's Roth IRA: Alpine Dynamic Dividend AOD 1,134 0.42 Matt's Roth IRA: Biomarin Pharmaceuticals BMRN 185 0.07 Matt's Roth IRA: Corcept Therapeutics CORT 108 0.04 N/A Matt's Roth IRA: Cyberonics CYBX $179 0.07 N

    8. Slightly Lowering BioMarin's Fair Value After Peg-Pal Delay, but Stock Remains Undervalued

      Commentary

      Fri, 2 May 2014

      Pal because of the redesign of its Phase III trial, and we've also pushed back the launches of other late stage candidates BMRN -673 and BMN-701, as we have factored delayed starts and longer enrollment periods into our analysis. Given the heavy investment

    9. Our Outlook for Health-Care Stocks

      Headlines

      Fri, 28 Jun 2013

      attractiveness, collaborative fit, and digestible size. Our top biotech picks are Onyx ONXX, Regeneron REGN, Incyte INCY, Biomarin BMRN , and Seattle Genetics SGEN. Valeant VRX made the biggest acquisition splash over the past few months, acquiring Bausch & Lomb

    10. Raising Our BioMarin Fair Value Estimate Based on Positive Long-Term Outlook

      Commentary

      Mon, 6 May 2013

      We're raising our fair value estimate for BioMarin BMRN to $71 per share from $59, after reassessing our long-term growth assumptions for the firm. Specifically, we have boosted

    « Prev12345Next »
    Content Partners